Afroj Sayma, Brannen Andrew D, Nasrin Shamima, Al Mouslem Abdulaziz, Hathcock Terri, Maxwell Herris, Rasmussen-Ivey Cody R, Sandage Mary J, Davis Edward W, Panizzi Peter, Wang Chengming, Liles Mark R
Department of Biological Sciences, Auburn University, Auburn, AL, United States.
Department of Drug Discovery and Development, Auburn University, Auburn, AL, United States.
Front Microbiol. 2021 Oct 8;12:746410. doi: 10.3389/fmicb.2021.746410. eCollection 2021.
The increasing frequency of antimicrobial resistance has spurred interest in identifying alternative therapeutants. We investigated the inhibitory capacity of strains in mouse and bovine models. Among multiple strains that inhibited growth , AP183 provided the most potent inhibition of proliferation and bioluminescence in a mouse cutaneous wound ( = 0.02). Histology revealed abundant Gram-positive cocci in control wounds that were reduced in AP183-treated tissues. Experiments were then conducted to evaluate the ability of AP183 to prevent biofilm formation on a tracheostomy tube substrate. AP183 could form a biofilm on a tracheostomy tube inner cannula substrate, and that this biofilm was antagonistic to colonization. AP183 was also observed to inhibit the growth of isolates originated from bovine mastitis cases. To evaluate the inflammatory response of mammary tissue to intramammary inoculation with AP183, we used high dose and low dose inocula in dairy cows. At the high dose, a significant increase in somatic cell count (SCC) and clinical mastitis was observed at all post-inoculation time points ( < 0.01), which resolved quickly compared to induced mastitis; in contrast, the lower dose of AP183 resulted in a slight increase of SCC and no clinical mastitis. In a subsequent experiment, all mammary quarters in four cows were induced to have grade 1 clinical mastitis by intramammary inoculation of a mastitis isolate; following mastitis induction, eight quarters were treated with AP183 and milk samples were collected from pretreatment and post-treatment samples for 9 days. In groups treated with AP183, SCC and abundance of decreased with significant reductions in after 3 days post-inoculation with AP183 ( = 0.04). A milk microbiome analysis revealed significant reductions in relative abundance in the AP183-treated group by 8 days post-inoculation ( = 0.02). These data indicate that AP183 can inhibit biofilm formation and its proliferation in murine and bovine disease models.
抗菌药物耐药性频率的增加激发了人们对寻找替代治疗药物的兴趣。我们在小鼠和牛模型中研究了菌株的抑制能力。在多种抑制生长的菌株中,AP183对小鼠皮肤伤口中的增殖和生物发光提供了最有效的抑制作用(P = 0.02)。组织学显示,对照伤口中有大量革兰氏阳性球菌,而在AP183处理的组织中数量减少。随后进行实验以评估AP183预防气管造口管基质上生物膜形成的能力。AP183可以在气管造口管内套管基质上形成生物膜,并且这种生物膜对定植具有拮抗作用。还观察到AP183抑制源自牛乳腺炎病例的分离株的生长。为了评估乳腺组织对乳腺内接种AP183的炎症反应,我们在奶牛中使用了高剂量和低剂量接种物。在高剂量时,在所有接种后时间点均观察到体细胞计数(SCC)和临床乳腺炎显著增加(P < 0.01),与诱导性乳腺炎相比,其消退迅速;相比之下,较低剂量的AP183导致SCC略有增加且无临床乳腺炎。在随后的实验中,通过乳腺内接种乳腺炎分离株,使四头奶牛的所有乳腺象限都诱发了1级临床乳腺炎;乳腺炎诱发后,对八个象限用AP183进行处理,并在预处理和处理后9天收集牛奶样本。在用AP183处理的组中,接种AP183后3天,SCC和的丰度降低,显著减少(P = 0.04)。牛奶微生物组分析显示,接种后8天,AP183处理组中的相对丰度显著降低(P = 0.02)。这些数据表明,AP183可以在小鼠和牛疾病模型中抑制生物膜形成及其增殖。